Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. Astellas Pharma US Inc.
CRL
•Astellas Pharma US Inc.

Astellas Pharma US Inc. – FDA CRL

Record Details

Astellas Pharma US, Inc. received a Complete Response Letter (CRL) from the FDA concerning its New Drug Application (NDA 209529) for solifenacin succinate oral suspension, 1 mg/mL, filed under section 505(b) of the Federal Food, Drug, and Cosmetic Act. The FDA determined that the application is not approvable in its current state due to significant deficiencies identified during a recent review and manufacturing facility inspection. The primary issues include objectionable conditions observed at a key manufacturing site. Furthermore, the quality of a critical raw material is insufficiently controlled, leading to drug product batches that fail to meet proposed specifications. The drug product’s specification and post-approval stability program also lack adequate test methods and acceptance criteria to ensure the product is free from objectionable microorganisms originating from the raw material. To resolve these, Astellas must submit comprehensive raw material characterization studies, investigations, and corrective actions. They need to establish and validate additional quality control tests for the raw material and provide data from three validation batches demonstrating product quality. Revisions to the drug product specification and stability program are required to incorporate microbial testing. Additionally, the company must update prescribing information, labeling, and provide a comprehensive safety update. Approval is contingent upon satisfactory resolution of all noted deficiencies.

Company
Astellas Pharma US Inc.
Product type
Drugs
Office
Office of Drug Evaluation II
Person
  • Jennifer M. LaMora
View Company Profile

ID · 38824898-0fd3-4732-a3c0-0e2b0ec6c098

Other documents for Astellas Pharma US Inc.
  • EIR - 2019-10-04October 4, 2019
  • CRL
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Astellas Pharma US Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.